Jupiter Neurosciences, Inc. (JUNS)
Automate Your Wheel Strategy on JUNS
With Tiblio's Option Bot, you can configure your own wheel strategy including JUNS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JUNS
- Rev/Share 0.0
- Book/Share 0.0017
- PB 308.2249
- Debt/Equity 3.1418
- CurrentRatio 0.6481
- ROIC -31.7829
- MktCap 17898262.0
- FreeCF/Share -0.198
- PFCF -2.6549
- PE -2.3294
- Debt/Assets 0.07
- DivYield 0
- ROE -3.5197
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company's Standby Equity Purchase Agreement.
Read More
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
Published: January 27, 2026 by: Accesswire
Sentiment: Neutral
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026. Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Read More
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio
Read More
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation
Read More
About Jupiter Neurosciences, Inc. (JUNS)
- IPO Date 2022-01-18
- Website https://www.jupiterorphan.com
- Industry Biotechnology
- CEO Christer Rosen
- Employees 4